COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Multiple Ascending Dose Study in Healthy Volunteers
Scientific title
A Phase I Single Center, Double-Blind, Placebo-Controlled, Multiple Dose-Ascending Study to Evaluate the Pharmacokinetics and Tolerability of CTP-730 Immediate Release at Steady State in Healthy Adults
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Treatment: Drugs - CTP-730
Treatment: Drugs - Placebo for CTP-730

Experimental: CTP-730 Low Dose or Matching Placebo - Capsule, once daily.

Experimental: CTP-730 Mid Dose or Matching Placebo - Capsule, once daily

Experimental: CTP-730 High Dose or Matching Placebo - Capsule, once daily.

Treatment: Drugs: CTP-730

Treatment: Drugs: Placebo for CTP-730

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Pharmacokinetic Profile - The primary pharmacokinetics parameters of interest will be time to attainment of steady state, and Cmax, Tmax, AUC0-24hr, AUClast and AUCinf at steady state
Timepoint [1] 0 0
96 hours
Primary outcome [2] 0 0
Number of Participants with Adverse Events as a Measure of Safety and Tolerability - Adverse events categorized by body system and MedDRA term
Timepoint [2] 0 0
24 hours

Key inclusion criteria
- Healthy adult males and females between 18 and 50 years of age.

- Body weight = 50 kg and BMI within the range of 18 to 30 kg/m2
Minimum age
18 Years
Maximum age
50 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Medical, psychiatric illness or history of depression that could, in the
investigator's opinion, compromise the subject's safety

- Significant medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from participating in the study.

- History of clinically significant central nervous system (eg, seizures), cardiac,
pulmonary, metabolic, renal, hepatic, or gastrointestinal (GI) conditions.

- PR interval = 220 msec or QRS duration = 120 msec or QTcB / QTcF interval > 450 msec
obtained at screening visit or prior to the first dose of study drug.

- Liver function tests greater than the upper limit of normal.

- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
virus surface antigen, or hepatitis C virus antibody at screening.

- Urinalysis positive for protein or glucose.

- A positive screen for alcohol, drugs of abuse, or tobacco use.

- Inability to comply with food and beverage restrictions during study participation.

- Donation or blood collection or acute loss of blood prior to screening.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Concert Pharmaceuticals

Ethics approval
Ethics application status

Brief summary
This study will assess in healthy male and female subjects the safety, tolerability and
pharmacokinetics (PK) profiles of Immediate Release CTP-730 at steady state following 7 days
of dosing. Three doses of Immediate Release (IR) CTP-730 capsules will be studied.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Ginny Braman
Address 0 0
Concert Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications